Top News
Latest News
INSIGHTS
16 Mar 2026
Inside the High-Tech Rebirth of ADCsPARTNERSHIPS
10 Mar 2026
New Roche Deal Targets B7H3 Tumors WorldwideINNOVATION
20 Feb 2026
Taiho’s Calculated Gamble on Precision ADCsREGULATORY
12 Feb 2026
A Faster Track for Myeloma Treatments?
Can Better ADC Engineering Unlock Solid Tumors?
INVESTMENT
9 Feb 2026
Solve Therapeutics raises $120M with backing from MSD and others, betting that smarter ADC design can finally unlock solid tumors
INSIGHTS
16 Mar 2026
Inside the High-Tech Rebirth of ADCs
Experts have revealed five pivotal shifts in drug design, moving toward a future of safer, integrated, and AI-driven cancer therapies
PARTNERSHIPS
10 Mar 2026
New Roche Deal Targets B7H3 Tumors Worldwide
Roche secures global rights to MediLink’s YL201 ADC, expanding its oncology pipeline and deepening cross-border biotech partnerships
INNOVATION
20 Feb 2026
Taiho’s Calculated Gamble on Precision ADCs
Taiho’s Araris deal highlights linker chemistry as a critical edge in building safer, more consistent antibody drug conjugates
REGULATORY
12 Feb 2026
A Faster Track for Myeloma Treatments?
Draft guidance elevates MRD and complete response, clearing a faster regulatory path for new multiple myeloma therapies
INVESTMENT
9 Feb 2026
Can Better ADC Engineering Unlock Solid Tumors?
Solve Therapeutics raises $120M with backing from MSD and others, betting that smarter ADC design can finally unlock solid tumors
TECHNOLOGY
4 Feb 2026
Why Antibody Drug Design Is Becoming an AI Problem
AI is reshaping antibody drug design as pharma turns to early partnerships to cut risk, speed timelines, and stay competitive
SUBSCRIBE FOR UPDATES
By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.